Muehrcke’s lines by Tavares, Nuno Teixeira et al.
Autopsy and Case Reports. ISSN 2236-1960. Copyright © 2018. This is an Open Access article distributed 
under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted 
non-commercial use, distribution, and reproduction in any medium provided the article is properly cited.
a Centro Hospitalar de São João, Serviço de Oncologia Médica. Porto, Portugal.
Muehrcke’s lines
Nuno Teixeira Tavaresa, Andreia Costaa, Margarida Damascenoa
How to cite: Tavares NT, Costa A, Damasceno M. Muehrcke’s lines. Autops Case Rep [Internet].2018;8(1):e2018014. 
http://dx.doi.org/10.4322/acr.2018.014
Image in Focus
Muehrcke’s lines (ML)—a rare presentation of 
apparent leukonychia1—were firstly described by 
Dr. Robert Muehrcke2 in 1956 in a subset of patients 
with hypoalbuminemia due to nephrotic syndrome and 
other causes. They are usually associated with periods 
of metabolic stress and hypoalbuminemia, such as 
those secondary to infections, severe malnutrition, 
chronic diseases (e.g. liver diseases, renal insufficiency, 
or pellagra) and chemotherapy drugs (most frequently 
doxorubicin and cyclophosphamide).1,3,4 Other causes 
not influenced by hypoalbuminemia have been 
proposed, such as ML induced by altitude in Mount 
Everest expeditions.5 ML typically fade with digital 
compression and are expected to disappear as long 
as the serum albumin levels increase.1
Leukonychia can be classified as true (an injury in 
the nail matrix leads to white bands that move with 
nail growth) or apparent (static white discoloration 
bands secondary to nail bed pathology).1 Mees’ lines 
are an example of true leukonychia, most notably 
secondary to arsenic trioxide poisoning, but also carbon 
monoxide, thallium, and chronic fluoride poisoning 
(fluorosis), infections (leprosy, tuberculosis, malaria, 
herpes zoster), Hodgkin lymphoma, acute myeloid 
leukemia, and chemotherapy.6-10 Unlike ML, Mees’ 
lines do not fade with digital compression, and they 
are expected to move along the nail growth. Besides 
ML, other examples of apparent leukonychia are 
Lindsay nails (also known as “half-and-half nails”) in 
uremic renal failure patients (normal proximal half and 
a brownish, discolored distal half-nail)9-12 and Terry 
nails in patients with congestive heart failure, cirrhosis, 
and adult-onset diabetes mellitus (white-colored 
proximal half and normal distal half).9,12 Beau’s lines 
Figure 1. A – Muehrcke’s lines shown in the fingernails of both hands; B – Muehrcke’s lines in detail.
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can be described as white depressions parallel to the 
lunula as a result of direct damage to the nail matrix 
keratinocytes.1 This disruption can be caused by 
antimitotic drugs (most often taxanes),12 but also it can 
be related to any severe systemic illness.9 Interestingly, 
the width of the lines are strictly related to the severity 
and the temporal evolution of the underlying disease.10
The pictures above (Figure 1) refer to a 66-year-old 
woman with stage IV sarcoidosis who was diagnosed 
with locally advanced breast carcinoma, luminal B 
Her-2 negative subtype. She started neoadjuvant 
chemotherapy with doxorubicin and cyclophosphamide, 
but was unable to proceed with the treatment after 
the third cycle due to subsequent hospital admissions 
(the first one due to febrile neutropenia and the 
following two due to hospital-acquired pneumonia) 
with unfavorable evolution with chronic hypoxemic 
respiratory failure and prolonged hypoalbuminemia 
(<25 g/L; normal range 38-51 g/L). Chemotherapy 
was canceled; the patient was started on anastrozole 
and was proposed for mastectomy. Examining the 
patient’s fingernails during the third admission, 
we documented three non-palpable white bands 
parallel to the lunula separated by the natural pink 
nail. These findings are consistent with ML. Since the 
lines were not present before the cancer diagnosis and 
treatment, we believe chemotherapy played a major 
role in the pathophysiology, enhancing the effect of 
the tumor-induced hypoalbuminemia. In this clinical 
setting, sarcoidosis can be considered a relevant 
chronic comorbidity that is probably less related to ML, 
since there are no clear data in the literature supporting 
this connection.
This manuscript was approved by the institution’s 
Ethics Committee after the patient signed an informed 
consent.
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